BAK and BAX: Therapeutic Targets for Acute Myocardial Infarction and Myocardial Ischemia-Reperfusion Injury

Area of Science:

• Cardiovascular Science
• Molecular Biology
• Cell Death Pathways

Background:

• Acute myocardial infarction (AMI) and subsequent reperfusion therapy cause significant myocardial cell death, contributing to heart failure.
• Apoptosis and necroptosis are the primary modes of cell death during myocardial ischemia-reperfusion injury (IRI).
• The limited regenerative capacity of the heart necessitates strategies to inhibit cell death for improved patient outcomes.

Purpose of the Study:

• To review the role of BCL2 family proteins in regulating apoptosis and necroptosis in the context of AMI and IRI.
• To explore upstream signaling pathways that modulate these cell death processes.
• To summarize recent advancements in targeting BAK and/or BAX for cardioprotection.

Main Methods:

• Review of existing literature on BCL2 family proteins, apoptosis, necroptosis, and myocardial infarction.
• Analysis of studies involving BAK/BAX modulation in animal models of AMI and IRI.
• Examination of signaling pathways converging on mitochondrial permeabilization (MOMP and MIMP).

Main Results:

• BCL2 family proteins regulate both apoptosis and necroptosis through BAK/BAX-mediated mitochondrial outer membrane permeabilization (MOMP) and inner membrane permeabilization (MIMP).
• BAK/BAX double knockout (DKO) mice exhibit reduced apoptosis, necroptosis, and infarct size in AMI models.
• Targeting BAK and/or BAX presents a promising strategy for reducing myocardial cell death.

Conclusions:

• Inhibiting myocardial apoptosis and necroptosis via BCL2 family protein modulation is crucial for managing AMI.
• Targeting BAK/BAX offers a potential therapeutic avenue for reducing infarct size and improving long-term outcomes in myocardial infarction.
• Targeted delivery of BAK/BAX inhibitors to cardiomyocytes could significantly decrease myocardial cell death.